MONTREAL, May 26, 2022 /CNW Telbec/ - Lumiera Health Inc. (TSXV: NHP) (the "Company" or "Lumiera "), a company specializing in the development and commercialization of natural health products, is pleased to announce the retail expansion of its Awaye™ pain relief cream. Awaye™ is now available at Rachelle Béry health food stores. Rachelle Béry, is a natural health food chain part of Sobeys Inc.'s retail network.
Rachelle Béry opened its first natural products grocery store over 35 years ago. Today, with 11 grocery stores and over 70 In-store locations in IGA supermarkets throughout Québec, the banner has become a leader in organic and natural products across the province.
"The Rachelle Béry brand is recognized as a trusted retailer of natural products by Québec consumers. Having Awaye™ on the shelves at Rachelle Béry represents not only a badge of quality but also a significant milestone for our product in terms of retail distribution," says Carlos Ponce, CEO of Lumiera." As per our previous announcements, we are pleased with Awaye™'s e-commerce progress and we are now focused on building retail distribution so that everyone has access to the natural pain relief that Awaye™ provides, regardless of where people shop. We are excited to working with our current and future retail partners to continue expanding distribution and consumer trial. This is another positive step on Awaye™'s accelerated growth plans and we look forward to sharing more details are we further expand distribution and availability."
Awaye™ provides a new generation of relief from acute and chronic pain by exploiting the CB2 receptors of the endocannabinoid system, the body's built-in pain and inflammation defense system. Awaye™ is a unique Health Canada approved topical cream that provides relief from pain through complimentary mechanisms of action not found in any other product currently available on the market.
For more information about Awaye™ products, visit www.awaye.ca
About Lumiera Health
Lumiera specializes in the development and commercialization of consumer products for the natural health industry. The Company sells herbal tonics and natural supplements through its Holizen Laboratories division, with a diverse portfolio including a line of innovative sleep aids. The Company is also commercializing a unique topical product line acting on the endocannabinoid system, without the use of cannabis, that provides an innovative solution for chronic pain and inflammation. A pioneer in the natural health innovation space, the Lumiera brand is rooted in the core values of science, nature and compassion. Our goal is to make people's lives better by developing natural health and wellness products that are effective, safe and trustworthy.
For more information visit: www.lumiera.ca.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Certain statements contained in this press release constitute "forward-looking information" as such term is defined in applicable Canadian securities legislation. The words "may", "would", "could", "should", "potential", "will", "seek", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions indicate such "forward-looking information" as they relate to Lumiera. All statements other than statements of historical fact may be forward-looking information. Such statements reflect Lumiera' current views and intentions with respect to future events, and current information available to Lumiera, and are subject to certain risks, uncertainties and assumptions. Such risks and uncertainties include, among others, the risk factors included in Lumiera' annual management's discussion and analysis for the year ended November 30, 2021, which is available under the issuer's SEDAR profile at www.sedar.com. Material factors or assumptions were applied in providing forward-looking information. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. Should any factor affect Lumiera in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, Lumiera does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and Lumiera undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.
SOURCE Lumiera Health Inc.
View original content: http://www.newswire.ca/en/releases/archive/May2022/26/c9269.html